Crohn ' s disease is often purely infl ammatory at presentation, but most patients develop strictures and fi stulae over time (complicated disease). Many studies have suggested that nucleotide-binding oligomerization domain 2 ( NOD2 ) mutations are associated with a varying but increased risk of complicated disease. An accurate and suffi ciently powerful predictor of complicated disease could justify the early use of biological therapy in high-risk individuals. We performed a systematic review and meta-analysis to obtain accurate estimates of the predictive power of the identifi ed mutations (such as p.R702W, P.G908R, and p.Leu1007fsX1008) in NOD2 for the risk of complicated disease.
INTRODUCTION
Crohn ' s disease is a chronic immune-mediated infl ammatory condition of the gastrointestinal tract. Complex interactions between the immune system and the intestinal luminal fl ora trigger chronic infl ammatory responses, which results in the development of intestinal fi brosis over time. Initially, the majority 1 of patients develop a purely infl ammatory presentation of disease ( 1, 2 ) . However, most patients eventually develop intestinal fi brosis, which leads to the development of severe complications, such as intestinal strictures and fi stulae.
Th e rate at which individuals develop stricturing or penetrating complications varies widely. Th e rate of progression seems to be unpredictable, although many attempts have been made to defi ne an " aggressive phenotype " ( 1,3 -6 ) . Th e goal of predicting disease phenotype is to identify patients at risk of more severe disease who may benefi t from early aggressive therapy. Th ere are two requisite conditions that must be fulfi lled for a predictive strategy to be successful. First, the predictive test must be sensitive and specifi c for complicated disease. Second, the group predicted to have complicated disease must have a proven response to a cost-eff ective change in therapy that results in a signifi cant change in the natural history of these patients.
Susceptibility genes for Crohn ' s disease have been recently elucidated. Th e fi rst and most promising identifi ed mutations are in the nucleotide-binding oligomerization domain 2 ( NOD2 ), also known as the caspase recruitment domain 15 ( CARD15 ) gene, located on chromosome 16q12. NOD2 / CARD15 has been identifi ed as a disease-susceptibility gene, which confers a risk for the development of Crohn ' s disease ( 7 -12 ) . Many studies have suggested that NOD2 mutations are associated with a varying but increased risk of complicated disease ( 10,13 -15 ) . Certain NOD2 mutations have been postulated to lead to more severe defects and thus predict more aggressive disease behavior ( 14,16 -18 ) . However, published data to date are confl icting as to the prognostic value of NOD2 genotyping ( 19 -21 ) .
Most studies to date have been focused on the risk of disease development, and do not specifi cally address disease severity. Relatively few studies have directly investigated the question of disease severity, although some of the large disease-susceptibility studies contain information on disease phenotype and severity. Published studies of disease phenotype have demonstrated varying degrees of risk attributable to NOD2 mutations ( 19, 20 ) . Some papers have focused on diff erences between specifi c NOD2 mutations, whereas others have focused on numbers of mutant alleles ( 10,22 -24 ) .
Predictive results vary widely across these studies. For genotyping patients to be useful in practice, an estimation of the risk of severe disease associated with a genotype would have to be clearly defi ned. If a method of predicting disease severity was accurate, the benefi ts to patient care would be tremendous. An accurate and suffi ciently powerful predictor of complicated disease, followed by targeted, cost-eff ective intervention for these patients could potentially change the natural history of Crohn ' s disease, and justify early use of expensive biological therapies in high-risk individuals.
Th ree major polymorphisms in the NOD2 gene have been reported to be associated with Crohn ' s disease. Th ese singlenucleotide polymorphisms include p.R702W, p.G908R, and p.Leu1007fsX1008. We performed a systematic review of the literature with meta-analysis to obtain accurate estimates of the predictive power of these identifi ed mutations (p.R702W, p.G908R, and p.Leu1007fsX1008) in NOD2 for the risk of complicated disease. Other minor alleles have been reported, and where suffi cient data exist, we attempted to include these data as well. We defi ned complicated disease as stricturing and / or fi stulizing Crohn ' s disease for the purposes of this study.
METHODS

Search strategies
Th is systematic review of the literature and meta-analysis was performed and reported according to standard guidelines for systematic review and meta-analysis of diagnostic studies ( 25 -28 ) . We conducted a computer-aided literature search of MEDLINE database (Ovid Technologies, New York, NY) from inception to 31 December 2009. Th e search strategy used free-text words and MeSH terms (( " genotype / " or " genotype.mp " or nod2 or card15 or " Nod2 Signaling Adaptor Protein / " ) and ( " exp Crohn Disease / " or " exp Infl ammatory Bowel Diseases / " ) and ( " Phenotype / " or " phenotype.mp " or " exp Intestinal Obstruction / " or " Constriction, Pathologic / " or " stenosis.mp " or " stricture.mp " or " fi brostenosing.mp " or " stricturing.mp " or " exp Fistula / " or " exp Intestinal Fistula / " or " exp Digestive System Fistula / " or " exp Fistula / " or " exp Gastric Fistula / " or " exp Rectovaginal Fistula / " or " exp Rectal Fistula / " or " penetrating.mp " )) to increase the sensitivity of the search strategy ( 29 ) .
We conducted an additional computer-aided literature search of the Embase database (Elsevier, New York, NY) from inception to 31 December 2009. Th e search strategy was as follows: ((nod2 or card15) and (stricture or stricturing or ' fi stula ' / exp or fi stula or fi stulizing or penetrating or ' phenotype ' / exp or phenotype or ' stenosis ' / exp or stenosis) and ( ' crohn disease ' / exp or ' crohn disease ' or ' regional enteritis ' / exp or ' regional enteritis ' )).
Th e search was not restricted to English-language publications. In addition, aft er study selection, we reviewed the bibliographies of the studies to identify any additional studies relevant to this topic. Additional searches through ISI Web of Science (Th omson Reuters, New York, NY) and Google Scholar (Google, Mountain View, CA) were performed to identify any additional publications that may have been missed with the aforementioned searches.
Study selection
Two independent reviewers (J.A. and S.C.R.) read the titles of all candidate articles. For those articles that were not excluded based solely on the title, we reviewed the abstract. We then retrieved the full text of published manuscripts that could not be excluded based on the title and abstract alone. Th e articles were read and checked for inclusion criteria independently. All discrepancies were resolved by consensus. Th e fi nal agreement between reviewers was 100 % for study selection.
Study inclusion / exclusion criteria
Th e selection criteria for inclusion of a study were: (i) clear statement of disease defi nition; (ii) clear statement of genotyping and which mutations were studied; (iii) classifi cation of disease phenotype by Vienna or Montreal classifi cation with non-overlapping phenotypes ( 6, 30 ) ; (iv) documentation of genotype by phenotype on individual level data (not population gene frequency data); and (v) if raw numbers of each genotype -phenotype combination could be found or clearly calculated from the published data.
Included studies
A total of 49 studies included in this meta-analysis comprised 8,893 patients with Crohn ' s disease, of whom 2,897 had NOD2 mutations ( Table 1 ) . Of the 33 studies documenting disease duration, these data included 64,955 patient-years of disease duration. Studies were weighted by median disease duration. Th e 16 studies not providing disease duration data were weighted at the level of the study with the shortest documented median disease duration (3.9 years).
Quality assessment
Th e selection criteria were clearly documented in 10 out of 49 studies. Th e description of phenotype was clearly documented in 12 studies. Th e description of the method for genotyping was present in all but six papers. Th e spectrum of patients was generally refl ective of clinical practice, except in four papers. Explicit documentation of how missing data were handled was present in only two papers, whereas eight papers clearly had missing data that were unaccounted for. Only 11 papers included documentation that those assessing phenotypes were blinded to the results of genotyping. A summary of the QUADAS criteria is depicted in Supplementary Figure 1 online. Exclusion criteria were: (i) duplicate publications of a primary study that contained all or a subset of the original data; (ii) studies presenting only gene frequency data; and (iii) studies involving patients with ulcerative colitis or indeterminate colitis. In cases of potential or suspected overlapping subject populations (based either on location or authorship), the latest publication or the study with the largest numbers of patients was included in the meta-analysis. All others were excluded.
Data extraction
Two independent reviewers (J.A. and S.C.R.) extracted the following data from the selected studies onto data abstraction forms: study characteristics (such as design, country, year of publication, setting / region, sample size, phenotype data, genotype data, age at diagnosis, disease duration), population (mean age, sex, number of patients with each disease phenotype, criteria for diagnosis, genotyping technique, criteria for defi nition of phenotype), and outcomes (numbers of each NOD2 allele mutation and genotype -phenotype combinations). Other variables that were sought included methods for handling indeterminate or missing data. Discrepancies were resolved by discussion and consensus with the senior author (P.D.R.H.). We included two Spanishlanguage papers because one author (J.A.) is literate in Spanish. We excluded one Polish, two Hungarian, and one German language paper as we had no available resources to assist in translation.
Aft er completion of manuscript review and data extraction, all included studies were reviewed for assessment of study quality. Manuscripts were assessed according to a modifi ed subset of the QUADAS (Quality Assessment Tool for Diagnostic Accuracy) guidelines ( 31 ) .
Statistical analysis
Th e primary outcome for this analysis was the diagnostic test performance of NOD2 genotyping for predicting Crohn ' s disease phenotype. We applied the bivariate random-eff ects regression model for treatment trial meta-analysis and modifi ed for synthesis of diagnostic test data assuming a binomial error distribution for sensitivity and specifi city ( 32, 33 ) . Sensitivity, specifi city, and diagnostic odds ratios with 95 % confi dence intervals (95 % CIs) were calculated. Th e diagnostic odds ratio is defi ned as the odds of having a positive test result (mutant allele present) in patients with disease fi nding (fi stulizing disease, etc.) compared with the odds of a positive test result in patients without the disease (no fi stulizing disease). Th e diagnostic odds ratio is a single indicator of test accuracy that combines data from sensitivity and specifi city ( 34 ) .
Th e heterogeneity of the results between the studies was assessed graphically by forest plots, and statistical assessment was performed with the χ 2 test of homogeneity and the inconsistency index ( I
2
) and Cochran ' s Q -test for non-combinability. Th e I 2 index describes the percentage of total variation across studies that are due to heterogeneity rather than chance. A value between 50 and 75 represents moderate heterogeneity ( 35 ) . A non-signifi cant Cochrane Q represents minimal heterogeneity, indicating that the studies can be combined.
Th e overall performance of NOD2 was assessed with summary receiver operating characteristic (ROC) curve. We analyzed the All studies included were assessed for quality. Specifi c items assessed included the presence of a clear description of selection criteria. Th e description of phenotyping was recorded as the reference standard.
Risk of complicated disease
Th e risk of complicated disease (stricturing or fi stulizing) was compared between patients with various predetermined combinations of NOD2 mutations ( Table 2 ) . Th e pooled relative risk (RR) of complicated disease with the presence of any (one or more) NOD2 mutant allele was 1.17 (95 % CI 1.10 -1.24; P < 0.001; When specifi c individual mutant alleles were assessed, p.G908R was the only allele found to have a signifi cant association with complicated disease. In 10 studies with suffi cient data to assess its aff ect, p.R702W was found to confer an RR of complicated disease When homozygous mutations were assessed for individual mutant alleles, p.Leu1007fsX1008 was the only allele found to have a signifi cant association with complicated disease. In 3 studies, p.R702W was found to confer an RR of complicated disease of 1. 
Risk of stricturing disease
Th e risk of stricturing disease was compared between patients with various predetermined combinations of NOD2 mutations. Th e pooled RR of stricturing disease with the presence of any (one or more) NOD2 mutant allele was 1.33 (95 % CI 1.15 -1.55; P < 0.001; Figure 3a ) across 35 studies. Th ere was moderate evidence of heterogeneity between studies ( I 2 = 67.5 % ; Cochran ' s Q 71.5, P = 0.001). Study-specifi c pooled sensitivities and specifi cities included a sensitivity of 0.39 (95 % CI 0.34 -0.45) and a specifi city of 0.73 (95 % CI 0.68 -0.76). In 12 studies in which there were suffi cient data to consider individual mutations, p.G908R was found to be associated with an RR of stricturing disease of 1.90 (95 % CI 1.17 -3.07; P = 0.009; I 2 = 56.1 % ; Q = 8.82, P = 0.27) with a sensitivity of 0.11 (95 % CI 0.07 -0.16) and a specifi city of 0.94 (95 % CI 0.89 -97). Th ere was no attributable risk for stricturing disease with either p.R702W ( P = 0.5) or p.Leu1007fsX1008 ( P = 0.95) mutations.
Risk of fi stulizing disease
Th e risk of fi stulizing disease was compared between patients with various predetermined combinations of NOD2 mutations. Th e pooled RR of fi stulizing disease with the presence of any (one or more) NOD2 mutant allele was 1.16 (95 % CI 1.05 -1.28; P < 0.003; Figure 3b ) across 36 studies. Th ere was little evidence of heterogeneity between studies ( I 2 = 27.3 % ; Cochran ' s Q 38.2, P = 0.3). Studyspecifi c sensitivities and specifi cities included a sensitivity of 0.34 (95 % CI 0.30 -0.38) and a specifi city of 0.73 (95 % CI 0.69 -0.76). In 9 studies, p.G908R was found to be associated with an RR of fi stulizing disease of 1.42 (95 % CI 1.06 -1.90; P = 0.02; I 2 = 26.2 % ; Q = 8.69, P = 0.28) with a sensitivity of 0.08 (95 % CI 0.05 -0.12) and a specifi city of 0.94 (95 % CI 0.89 -96). In 12 studies, there was no attributable risk for fi stulizing disease with p.R702W ( P = 0.13) or p.Leu1007fsX1008 ( P = 0.66) mutations.
Risk of perianal disease
Perianal disease was reported separately from stricturing or fi stulizing phenotype in 17 manuscripts (3,836 patients). When this end point was analyzed, there was no increased or decreased risk of perianal disease associated with the presence of any NOD2 Figure 6 online).
Risk of surgery
Th e risk of patients undergoing any surgery specifi cally for Crohn ' s disease was reported in 17 studies including 3,643 patients. Th e risk of surgery was found to be increased if one or more NOD2 mutant alleles were present (RR 1.58; 95 % CI 1.38 -1.80; P < 0.001; 
Diagnostic accuracy
Th e summary statistics for the prognostic value of NOD2 mutations for complicated disease are listed in Lappalainen (2008) Laghi (2005) Linskens (2004) Vermeire (2002) Ferreira (2005) Giachino (2004) Heresbach (2004) Protic (2008) Brant (2003) Fidder (2003) Fernandez (2004) Louis ( Cucchiara (2007) Rigoli (2008) Annese (2005) Smith (2004) Rodrigo (2007) Tomer (2003) Dassopoulos (2009) Shaoul (2009) Canto (2007) Sun (2003) Alvarez−Lobos (2007) Vind (2005) Chua (2009) Maconi (2009) Tekin (2009 
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Effect of diagnostic threshold
Th e sensitivity and specifi city of the presence of any NOD2 mutant alleles for complicated disease in each study are displayed on the summary ROC diagram. Th e summary ROC curve and the summary operating point (with 95 % confi dence contour) are shown in relation to the individual studies. It must be noted that a coin fl ip has a diagnostic accuracy of 0.5. Th e AuROC was 0.56 for complicated disease ( Figure 5b ) and 0.54 for perianal disease, consistent with low diagnostic accuracy. Th e AuROC for stricturing disease was 0.61, the AuROC for fi stulizing disease was 0.54, and the AuROC was 0.63 for surgery for Crohn ' s disease all of which represent poor diagnostic accuracy (see Supplementary Figure 7 
DISCUSSION
NOD2 / CARD15 was identifi ed to be associated with Crohn ' s disease. Th ere is abundant evidence supporting NOD2 as a susceptibility allele conferring risk for developing Crohn ' s disease. As the early studies of NOD2 , and with the later advent of other genes associated with Crohn ' s disease, interest has grown toward identifying specifi c mutations that may be responsible for distinct disease behavior phenotypes.
Overall (I −2 = 52.9%, P = 0.007) Alvarez−Lobos (2007) Lesage (2002) Cucchiara (2007) Annese (2005) De Diego (2006) Canto (2007) Mendoza (2003) Laghi (2005) Fernandez (2004) Hsiao (2007) Maconi (2009) Sabate (2008) Lakatos (2005) Ahmad (2002) Tomer (2003) Brant (2003) Büning (2004) Study ID Fidder (2003) Törkvist ( Esters (2004) Büning (2004) Giachino (2004) Schoepfer ( Tomer (2003) Lappalainen (2008) Cucchiara ( phenotype prediction will require a multifactorial approach, which will include environmental factors, genetic factors, medication exposure, smoking, initial clinical presentation, etc. Th e fi ndings of this meta-analysis suggest that the presence of two mutant NOD2 alleles is quite specifi c for future complicated disease. Although the sensitivity is poor and the AuROC is poor, the high degree of specifi city may be suffi cient to recommend testing for double mutations if we can identify therapies that can truly change the outcomes for this high-risk stratum of patients. Testing for double mutations would likely miss many patients with aggressive disease. However, the presence of double mutations, Th ere have been confl icting reports from early in the literature as to the prognostic value of NOD2 . Abreu et al. ( 10 ) in 2002 found that NOD2 mutations were specifi cally associated with fi brostenosing disease and not penetrating disease. Th at same year, Lesage et al. ( 24 ) , found no association between NOD2 mutations and specifi c disease phenotypes. Alvarez-Lobos et al. ( 13 ) and Ince et al. ( 21 ) showed an association between NOD2 mutations and increased surgical rates in Crohn ' s disease, whereas Baptista et al. ( 19 ) found no measurable associations with disease behavior could be detected at all.
Th ere have been a number of small meta-analyses that have looked to answer these questions, but no full review of the literature to date exists ( 22, 42, 43 ) . We undertook a full systematic review of the published literature to gain a better understanding as to how the presence of NOD2 mutations modifi es disease behavior.
Th is meta-analysis showed that the presence of a single NOD2 / CARD15 mutation has poor predictive ability for disease phenotype in Crohn ' s disease with an AuROC of 0.56. Summary estimates showed poor sensitivity and fairly low specifi city for aggressive stenosing or fi stulizing phenotypes. However, the presence of two mutations in NOD2 (either homozygous or complex heterozygous) has a high degree of specifi city for aggressive disease phenotype, although the sensitivity and AuROC remain poor. Th e presence of homozygous mutations in NOD2 for p.Leu1007fsX1008 has an even higher degree of specifi city for aggressive disease phenotype, although the sensitivity remains poor. Th ese results show that the presence of multiple mutations identifi es a particularly high-risk group, although this is a very insensitive prognostic test. In contrast, the presence of single mutations in NOD2 is not a reliable predictor of disease phenotype.
Th ese fi ndings do not minimize the role NOD2 and other genetic mutations have in the development of Crohn ' s disease. NOD2 has a clear role as a susceptibility gene for the risk of development of Crohn ' s disease. However, at this point, the ability of NOD2 to predict disease severity is limited to patients with multiple mutant alleles. It is clear that genetics has a key role in the susceptibility to developing Crohn ' s disease, and likely has a role in disease behavior. Th e pathophysiology is complex, and the role genetics has is far more nuanced than the presence or absence of one mutation determining a certain disease behavior. More likely, a reliable disease Summary estimates for all the studies for any NOD2 mutation predicting complicated (stricturing or fi stulizing) disease. particularly mutations in p.Leu1007fsX1008, does identify a highrisk stratum of reagent-grade patients that should be identifi ed and analyzed as a distinct subgroup in clinical trials. If prospective trials can show a change in outcomes in these patients, this would be a strong justifi cation for targeted top-down therapy in this group of high-risk patients to prevent stricturing or fi stulizing complications.
Th e other major fi nding of this meta-analysis is the lack of prognostic value of the presence of one mutant allele for predicting Crohn ' s disease behavior. Although we specifi cally studied NOD2 mutations, recent genome-wide association studies have identifi ed numerous other genes that contribute to the susceptibility of developing Crohn ' s disease ( 44 -46 ) . It is likely that the level at which genetics contributes to phenotypic disease expression is complex and multiple risk alleles contribute to complex interactions. Further studies addressing disease behavior will likely require large-scale, multicenter trials to obtain suffi cient clinical data to accurately ascertain the cumulative risk from clinical, genetic, and environmental factors. Once additional predictive factors are identifi ed and validated, we will be better able to study targeted therapies in high-risk patients.
